the aid library

LIST OPTIONS

Filter

1074

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (503)

View PDF (721)

Interim National Guidelines for Monkeypox Outbreak Response

Federal Ministry of Health - Nigeria Centre for Disease Contro (2017) C2

This document provides information and recommendations for action, based on the current available knowledge around monkeypox. It is a first draft which will be updated in light of evolving evidence and additional information as they become available.

Download (1284)

View PDF (2148)

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended

Prof. G. N. Lule, Dr. B. Nyawira Gastroenterology Society of Kenya , Republic of Keny (2015) C1

Download (187)

View PDF (255)

The ACT-Accelerator: Two years of impact

World Health Organization WHO (2022) C_WHO

The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.

Download (277)

View PDF (291)

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance

World Health Organization WHO (2021) C_WHO

An Action Framework and annexe to Immunization Agenda 2030 (Draft version) 27 January 2021

Download (213)

View PDF (221)

Health system considerations: when influenza meets COVID-19: preparedness and response measures when COVID-19, influenza and acute respiratory infections coincide in the WHO European Region

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

revised version December 2020

Download (165)

View PDF (215)

WHO Drug Information - Volume 36, No. 4

World Health Organisation (WHO) (2023) C_WHO

Pharmaceutical News Evaluation of Saccharide Content of the WHO 2nd International Standard for Haemophilus Influenzae Polysaccharide Polyribosyl Ribitol Phosphate (PRP) by HPAECPAD Analysis Following Acid Hydrolysis Consultation Documents Lamivudine and tenofovir disoproxil fumarate tablets (lami... more

Download (1225)

View PDF (2308)

Guideline for Hand Hygiene in Health-Care Settings

Centers for Disease Control and Prevention CDC (2002)

Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force

Download (803)

View PDF (1336)

Zika Virus Research Agenda - October 2016

World Health Organization WHO (2016) C_WHO

Download (453)

View PDF (336)

Management of Tuberculosis: A Guide to the Essentials of Good Clinical Practice
recommended

International Union Against Tuberculosis and Lung Disease (2019) C1

The 7th edition of the Orange Guide provides practical guidance to health workers on the front line of TB control. It includes sections on HIV, MDR-TB and a review of the recommended treatment regimens

Download (2714)

View PDF (4239)

National List of Essential Medicines for Adults Rwanda 6th edition

Republic of Rwanda, Ministry of Health (2015) C1

The essential medicines are those that meet the priority needs of the healthcare of the population. While reviewing the 5th edition of the essential Medicines, special attention focused on the health sector policy. Indeed, medicines play an important role in protecting, maintaining and restoring th... more

Download (809)

View PDF (1520)

Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents Including Post-exposure Prophylaxis

Ministry of Health & Family Welfare Government of India Ministry of Health & Family Welfare Government of India (2007) C1

Download (221)

View PDF (217)

Use of alternative interferon-gamma release assays for the diagnosis of TB infection: WHO policy statement

World Health Organization WHO (2022) C_WHO

Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij... more

Download (173)

View PDF (214)

COVID-19: стратегический план по обеспечению готовности и реагирования. Руководство оперативному планированию, 1 февраля 2021 г. – 31 января 2022 г.

World Health Organization WHO (2021) C_WHO

Download (162)

View PDF (198)

Global Programme to Eliminate Lymphatic Filariasis

World Health Organization WHO (2013) C_WHO

The document explains why vector control is important in national programmes and describes the preparation of a tailor-made vector control plan for national programmes. It outlines entomological procedures for regular and specific vector control and how data should be analysed for better overall und... more

Download (214)

View PDF (219)

Human African trypanosomiasis. Seminar

Büscher P., Cecchi G., Jamonneau V. et al (2017) C2

The Lancet Volume 390, Issue 10110p2397-2409November 25, 2017. Human African trypanosomiasis (HAT), also called sleeping sickness, is a parasitic infection that almost invariably progresses to death, unless treatment is provided. HAT caused devastating epidemics during the 20th century. Thanks to ... more

Download (571)

View PDF (787)

Guidelines for antiretroviral therapy in Ghana

Ghana AIDS Commission (2010) C1

External Link

Novel vaccination approaches to prevent tuberculosis in children

J. A. Triccas, C. Counoupas Pneumonia; BioMed Central (2016) CC

Review Triccas and Counoupas Pneumonia (2016) 8:18; DOI 10.1186/s41479-016-0020-z

Download (197)

View PDF (282)

Ukraine HIV Program Efficiency Study: Can Ukraine improve value for money in HIV service delivery?

International Bank for Reconstruction and Development The World Bank (2019) C2

Accessed: 04.10.2019 The data collection process was organized by UCDC Director, Natalia Nizova, and M&E Department Head, Igor Kuzin, and implemented by M&E specialists from oblast AIDS Centers: Zhanna Antonenko, Oksana Gorbachuk, Volodymyr Zahorovskyi (Kiev City); Anna Lopatenko, Irina Kozina, I... more

Download (136)

View PDF (189)

WHO implementation tool for pre-exposure prophylaxis of HIV infection - Module 9

World Health Organization (WHO) World Health Organization (WHO) (2017) C_WHO

Module 9 Strategic planning July 2017 Module 9: Strategic planning. As WHO recommends offering PrEP to people at substantial HIV risk, this module offers public health guidance for policy-makers on how to prioritize services, in order to reach those who could benefit most from PrEP, and in wh... more

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya recommended

Management of Tuberculosis: A Guide to the Essentials of Good Clinical Practice recommended

Guidelines for the Treatment of Chronic Hepatitis B and C Viral Infections in Kenya
recommended

Management of Tuberculosis: A Guide to the Essentials of Good Clinical Practice
recommended